title: Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients.
abstract: BACKGROUND
  Bone metabolism is a dynamic process that is influenced by food ingestion. Endogenous incretins have been shown to be important regulators of bone turnover. The aim of the present study was to assess whether a dipeptidylpeptidase (DPP)-4 inhibitor affects markers of bone resorption and calcium homeostasis.
  
  
  METHODS
  The present study was a single-center, double blind, randomized clinical trail. Fifty-nine drug-naïve patients with type 2 diabetes (T2D) were randomized to either 1 year treatment with the DPP-4 inhibitor vildagliptin (100 mg, once daily; n = 29) or placebo (n = 30). Patients received a standardized breakfast after measurement of serum concentrations of cross-linked C-terminal telopeptide (s-CTx), a bone resorption marker influenced by food intake, before and after 50 weeks treatment.
  
  
  RESULTS
  Vildagliptin did not change postprandial s-CTx concentrations compared with pretreatment levels (between-group ratio 1.15 ± 0.17; P = 0.320). Fasting serum alkaline phosphatase, calcium, and phosphate were also unaffected y 1 year treatment with vildagliptin.
  
  
  CONCLUSIONS
  Treatment with vildagliptin for 1 year was not associated with changes in markers of bone resorption and calcium homeostasis in drug-naïve patients with T2D and mild hyperglycemia.
authors: Diabetes Center, Department of Internal Medicine, Section of Endocrinology, VU University Medical Center, Amsterdam, The Netherlands. mcmbunck@vumc.nl
authors: Mathijs C
authors: MC
authors: Bunck
authors: Marieke
authors: M
authors: Poelma
authors: E Marelise
authors: EM
authors: Eekhoff
authors: Anja
authors: A
authors: Schweizer
authors: Robert J
authors: RJ
authors: Heine
authors: Giel
authors: G
authors: Nijpels
authors: James E
authors: JE
authors: Foley
authors: Michaela
authors: M
authors: Diamant
mesh_terms: D000218:Adamantane / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D001862:Bone Resorption / Q000097:blood / Q000378:metabolism*; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D002118:Calcium / Q000097:blood / Q000378:metabolism*; D024042:Collagen Type I / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000097:blood; D006706:Homeostasis; D006801:Humans; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D009570:Nitriles / Q000009:adverse effects / Q000627:therapeutic use*; D010455:Peptides / Q000097:blood; D010710:Phosphates / Q000097:blood; D019518:Postprandial Period; D011759:Pyrrolidines / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D000077597:Vildagliptin
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D024042:Collagen Type I; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007328:Insulin; D009570:Nitriles; D010455:Peptides; D010710:Phosphates; D011759:Pyrrolidines; C052929:collagen type I trimeric cross-linked peptide; D052216:Glucagon-Like Peptide 1; D000469:Alkaline Phosphatase; D000077597:Vildagliptin; D000218:Adamantane; D002118:Calcium